Their results showed that treatment of cultured fibroblasts or localized injection of CXCL17 in a bleomycin-induced SSc mouse model increased miR-29 and matrix metalloproteinase 1 (MMP-1) expression and decreased type I collagen expression and skin fibrosis in the mouse model (114). Here, CXCL17 is linked to systemic sclerosis.